Search Within

Mrinal M Gounder

Formats
  1. Meeting Abstract (119)
  2. Journal Article (98)
  3. Review (4)
  4. Guidelines (2)
  5. Research Letter (2)
  6. Book Section (1)
  7. Correspondence (1)
  8. Editorial (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (229)
  2. Sarcoma Service (229)
  3. Solid Tumor Oncology Division (229)
  4. GSK Faculty (87)
  5. Hematologic Malignancies, Division of (85)
  6. Tow Center for Developmental Oncology (TCDO) (83)

More Groups

People
  1. William Tap (78)
  2. Mary Keohan (73)
  3. Sandra D'Angelo (73)
  4. Mark Dickson (70)
  5. Ping Chi (57)
  6. Li-Xuan Qin (52)

More People

Years
  1. 2025 (6)
  2. 2024 (17)
  3. 2023 (21)
  4. 2022 (36)
  5. 2021 (16)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (86)
  2. Annals of Oncology (24)
  3. Clinical Cancer Research (20)
  4. Cancer (7)
  5. The Oncologist (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (88)
  2. Oxford University Press (30)
  3. American Association for Cancer Research (29)
  4. Springer (14)
  5. Elsevier Inc. (11)
  6. Nature Publishing Group (10)

More Publishers

Results (229)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
    Meeting Abstract

    Postel-Vinay, S.; Italiano, A.; Martin Romano, P.; Cassier, P. A.; Siu, L. L.; Lossos, I. S.; Hilton, J. F.; Mckean, M. A.; Strauss, J.; Falchook, G. S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • The genetic landscape of SMARCB1 alterations in SMARCB1-deficient spectrum of mesenchymal neoplasms
    Journal Article

    Dermawan, J. K.; Singer, S.; Tap, W. D.; Nacev, B. A.; Chi, P.; Wexler, L. H.; Ortiz, M. V.; Gounder, M.; Antonescu, C. R.
    Modern Pathology (2022)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors
    Meeting Abstract

    Yamamoto, N.; Hafez, N.; Tolcher, A. W.; Teufel, M.; Geng, J.; Svensson, L.; Lahmar, M.; Gounder, M. M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma
    Meeting Abstract

    Slotkin, E. K.; Mauguen, A.; Ortiz, M. V.; Dela Cruz, F. S.; O'Donohue, T.; Kinnaman, M. D.; Meyers, P. A.; Wexler, L. H.; Rodriguez, S.; Avutu, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition
    Meeting Abstract

    Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
    Meeting Abstract

    Gounder, M. M.; Yamamoto, N.; Patel, M. R.; Bauer, T. M.; Schöffski, P.; Grempler, R.; Durland-Busbice, S.; Geng, J.; Maerten, A.; LoRusso, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save